SCHEMBL3482800

SCHEMBL3482800

CC(C)CCN1C(=O)C=CC1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 9/20 0.54
FAAH O00519 3/20 0.54
ALDH1A1 P00352 3/20 0.52
LMNA P02545 2/20 0.52
MAPT P10636 2/20 0.52
NPSR1 Q6W5P4 2/20 0.52
TLR9 Q9NR96 2/20 0.52
HSP90AA1 P07900 1/20 0.52
TP53 P04637 1/20 0.52
PKM P14618 1/20 0.52
HPGD P15428 1/20 0.52
XBP1 P17861 1/20 0.52
MAPK1 P28482 1/20 0.52
HTT P42858 1/20 0.52
RECQL P46063 1/20 0.52
RAB9A P51151 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
GPR35 Q9HC97 1/20 0.52
GPR55 Q9Y2T6 1/20 0.52
PTGS1 P23219 7/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3482198 0.86 MGLL (0.62) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL16307669 0.86 MGLL (0.40) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL406101 0.85 MGLL (0.67) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL16322608 0.84 MGLL (0.48) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL11128738 0.84 MGLL (0.52) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL14962677 0.83 MGLL (0.68) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL14868080 0.83 MGLL (0.68) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL14868075 0.83 MGLL (0.68) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL13078197 0.83 MGLL (0.68) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL22544689 0.82 MGLL (0.50) MGLLFAAHALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4517397-A1 OPTICAL RESIN, AND OPTICAL FILM, POLARIZING PLATE, SURFACE PLATE, IMAGE DISPLAY PANEL, IMAGE DISPLAY DEVICE, AND MOLDED PRODUCT FOR OPTICS USING SAID OPTICAL RESIN Dai Nippon Printing Co., Ltd. (JP) 2025-03-05 EP disclosed
US-12036319-B2 Polyvalent sting activating compositions and uses thereof THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-07-16 US disclosed
WO-2024052333-A1 MULTIVALENT FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS PHILOCHEM AG (CH) 2024-03-14 WO disclosed
US-20230279186-A1 Hydrogels Based On Functionalized Polysaccharides ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) 2023-09-07 US disclosed
US-20230279186-A1 Hydrogels Based On Functionalized Polysaccharides ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) 2023-09-07 US disclosed
US-20230211008-A1 CONJUGATES ORUM THERAPEUTICS, INC. (KR) 2023-07-06 US disclosed
US-11691982-B2 Thailanstatin analogs PH PHARMA CO., LTD. (KR) 2023-07-04 US disclosed
US-11691982-B2 Thailanstatin analogs PH PHARMA CO., LTD. (KR) 2023-07-04 US disclosed
WO-2023018743-A1 PH-RESPONSIVE NANOPARTICLE FOR DELIVERY OF RIBONUCLEOPROTEINS WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2023-02-16 WO disclosed
US-20210188880-A1 ONE-STEP, FAST, 18F-19F ISOTOPIC EXCHANGE RADIOLABELING OF DIFLUORO-DIOXABORININS AND USE OF SUCH COMPOUNDS IN TREATMENT UNIV CORNELL (US) 2021-06-24 US disclosed
CN-101948709-A Triazine derivate extreme-pressure antiwear agent containing ester group and preparation method thereof UNIV SHANGHAI JIAOTONG 2011-01-19 CN disclosed
US-20100240855-A1 Compound having silsesquioxane skeleton and its polymer JNC CORPORATION (JP) 2010-09-23 US disclosed
CN-1775825-B Polyasparagines BAYER MATERIALSCIENCE AG 2010-08-25 CN disclosed
US-7705105-B2 A cyclic polymer of silsesquioxane skeleton with side chains formed byhydrosilation of an unsaturated end group containing an active polymerfunctional group; polyimidesiloxane copolymers; polyestersiloxane copolymers; high molecular weight; thin films; strength; heat resistance;waterproofing; CHISSO PETROCHEMICAL CORPORATION (JP) 2010-04-27 US disclosed
US-7482376-B2 Conjugated complement cascade inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2009-01-27 US disclosed
WO-2007127473-A2 POLY (ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS INTEZYNE TECHNOLOGIES, INC. (US) 2007-11-08 WO disclosed
US-20070190344-A1 Verification of translation JNC CORPORATION (JP) 2007-08-16 US disclosed
CN-1910146-A Aspartic acid esters useful as components in coating compositions and methods for making the same BAYER MATERIALSCIENCE LLC (US) 2007-02-07 CN disclosed
CN-1775825-A Polyasparagines BAYER MATERIALSCIENCE AG (DE) 2006-05-24 CN disclosed
US-20050009982-A1 Compound having silsesquioxane skeleton and its polymer CHISSO CORPORATION (JP) 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188880-A1 ONE-STEP, FAST, 18F-19F ISOTOPIC EXCHANGE RADIOLABELING OF DIFLUORO-DIOXABORININS AND USE OF SUCH COMPOUNDS IN TREATMENT AFF1, FGFR1, AFF2 MGLL 507/4885FAAH 177/4885ALDH1A1 2523/4885
US-12036319-B2 Polyvalent sting activating compositions and uses thereof STING1, CGAS, TLR7 MGLL 2017/4885FAAH 4082/4885ALDH1A1 4874/4885
US-11691982-B2 Thailanstatin analogs CD47, SUGT1, TPT1 MGLL 4867/4885FAAH 4794/4885ALDH1A1 2912/4885
US-20050009982-A1 Compound having silsesquioxane skeleton and its polymer C1S, H1-4, H1-0 MGLL 4700/4885FAAH 4471/4885ALDH1A1 1780/4885
US-20230279186-A1 Hydrogels Based On Functionalized Polysaccharides CD44, ALG1, CSGALNACT1 MGLL 414/4885FAAH 2346/4885ALDH1A1 447/4885
US-20230211008-A1 CONJUGATES CD74, CD47, HLA-DRB1 MGLL 3521/4885FAAH 3933/4885ALDH1A1 1667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.